Abstract
Purpose
Aciclovir (ACV), valaciclovir (VACV) and famciclovir (FCV) are used for systemic infections caused by herpes virus. In Japan, only topical ACV is permitted for use against herpetic keratitis. We investigated the effectiveness of topical ACV, oral VACV and oral FCV on mouse epithelial herpetic keratitis.
Methods
C57/BL76 mice were inoculated with HSV-1 McKrae strain in the cornea. Once infection was confirmed 4 days after inoculation, topical ACV, oral VACV and FCV were started and administered for 5 days. Control groups were given either topical or oral saline. On days 2, 4, 6 and 10 after medication started, tears, eyeballs, and trigeminal ganglia were examined using viral culture and real-time PCR.
Results
Viral culture of tears detected no HSV in the topical ACV group on day 4 after administration start; with similar results for the oral VACV group on day 4; and the oral FCV group on day 6. Real-time PCR of the eyeballs showed significant decrease of HSV DNA copy number in the topical ACV group on days 4 and 6 compared to the topical saline group. Real-time PCR of the trigeminal ganglia showed significant decrease of HSV DNA copy number in the oral VACV group on days 4 and 6, and in the oral FCV group on day 6 compared to the oral saline group.
Conclusion
We suggest that 5-day administration of topical ACV, oral VACV and oral FCV are effective for mouse epithelial herpetic keratitis and sufficiently decrease HSV amounts in the ocular surface and eyeballs.
Similar content being viewed by others
References
Nesburn AB, Dickinson R, Radnoti M. The effect of trigeminal nerve and ganglion manipulation on recurrence of ocular herpes simplex in rabbits. Invest Ophthalmol. 1976;15:726–31.
Hill JM, Wen R, Halford WP. Quantitative analysis of polymerase chain reaction products by dot blot. Anal Biochem. 1996;235:44–8.
Stevens JG. Human herpesviruses: a consideration of the latent state. Microbiol Rev. 1989;53:318–32.
Cohrs RJ, Gilden DH. Human herpesvirus latency. Brain Pathol. 2001;11:465–74.
Sawtell NM, Thompson RL. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol. 1992;66:2150–6.
Varnell ED, Kaufman HE, Hill JM, Thompson HW. Cold stress-induced recurrences of herpetic keratitis in the squirrel monkey. Invest Ophthalmol Vis Sci. 1995;36:1181–3.
Haruta Y, Rootman DS, Xie LX, Kiritoshi A, Hill JM. Recurrent HSV-1 corneal lesions in rabbits induced by cyclophosphamide and dexamethasone. Invest Ophthalmol Vis Sci. 1989;30:371–6.
Cook SD, Paveloff MJ, Doucet JJ, Cottingham AJ, Sedarati F, Hill JM. Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants. Invest Ophthalmol Vis Sci. 1991;32:1558–61.
Higaki S, Gebhardt BM, Lukiw WJ, Thompson HW, Hill JM. Effect of immunosuppression on gene expression in the HSV-1 latently infected mouse trigeminal ganglion. Invest Ophthalmol Vis Sci. 2002;43:1862–9.
Higaki S, Gebhardt B, Lukiw W, Thompson H, Hill J. Gene expression profiling in the HSV-1 latently infected mouse trigeminal ganglia following hyperthermic stress. Curr Eye Res. 2003;26:231–8.
O’Brien JJ, Campoli-Richards DM. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989;37:233–309.
Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S, Roberts G, et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol Suppl. 1993;1:139–45.
Bacon TH, Howard BA, Spender LC, Boyd MR. Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother. 1996;37:303–13.
Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl) guanine; penciclovir]. Antimicrob Agents Chemother. 1989;33:1765–73.
Itahashi M, Higaki S, Shimomura Y. Effects of anti herpetic drugs on mice with herpetic epithelial keratitis after reactivation of herpes simplex virus type 1. Semin Ophthalmol. 2008;23:241–7.
Higaki S, Itahashi M, Deai T, Fukuda M, Shimomura Y. Effect of oral valaciclovir on herpetic keratitis. Cornea. 2006;25:S64–7.
Higaki S, Watanabe K, Itahashi M, Shimomura Y. Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. Curr Eye Res. 2009;34:171–6.
Shimomura Y, Higaki S, Watanabe K. Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate. Jpn J Ophthalmol. 2010;54:187–90.
Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med. 1998;339:300–6.
Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol. 2000;118:1030–6.
Loutsch JM, Sainz B Jr, Marquart ME, Zheng X, Kesavan P, Higaki S, et al. Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. Antimicrob Agents Chemother. 2001;45:2044–53.
Romanowski EG, Bartels SP, Gordon YJ. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest Ophthalmol Vis Sci. 1999;40:378–84.
Sozen E, Avunduk AM, Akyol N. Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial. Chemotherapy. 2005;52:29–31.
LeBlanc RA, Pesnicak L, Godleski M, Straus SE. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. J Infect Dis. 1999;180:594–9.
Sawtell NM, Thompson RL, Stanberry LR, Bernstein DI. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis. 2001;184:964–71.
Acknowledgments
We thank Ms. Yukiko Mimuro for her editing of the manuscript and Ms. Mayumi Mizuno for her technical assistance.
Conflicts of interest
S. Komoto, None; S. Higaki, None; M. Fukuda, None; Y. Shimomura, None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Komoto, S., Higaki, S., Fukuda, M. et al. Effects of antiviral medications on herpetic epithelial keratitis in mice. Jpn J Ophthalmol 59, 194–200 (2015). https://doi.org/10.1007/s10384-015-0375-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-015-0375-3